// App-Quantinova.ai

: Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Researchers

Presenter

  • Johanna A. Kremer Hovinga

Principal Investigators

  • Marie Scully

  • Spero R Cataland

  • Flora Peyvandi

  • Paul Coppo

  • Paul Knbl

  • Javier De La Rubia

  • Katerina Pavenski

  • Jessica Minkue

  • Rui Passos Sousa

  • Filip Callewaert

  • Hilde De Winter

  • Ara Metjian

Medical Centers

  • Hematology and Central Hematology Laboratory, Inselspital, University Hospital of Bern, Bern, Switzerland

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Hemophilia & Thrombosis Centre, Milano, Italy

  • EBMT Department of Haematology, Saint Antoine Hospital, Paris, France

  • Department of Medicine 1, Division of Hematology and Hemostasis,Medical University of Vienna,Vienna,Österreich

  • Hematology Department,Universidad Católica de Valencia Hospital Doctor Peset,Valencia,Spain

  • Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital/Research Institute, Toronto, Canada

  • Ablynx, Zwijnaarde, Belgium

  • Ablynx NV, Ghent (zwijnaarde), Belgium

  • Clinical Development, Ablynx NV, Belgium, Belgium

  • Clinical Development, Ablynx NV, Zwijnaarde, Belgium

  • Division of Cardiology, Duke University School of Medicine, Durham, NC

Locations

  • Switzerland

  • United Kingdom

  • United States

  • Italy

  • France

  • Austria

  • Spain

  • Canada

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

Disease

  • Thrombotic thrombocytopenic purpura

Biomarkers

  • N/A

Drug/Treatment

  • ALX-0081

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved